Best of 2023: New Laboratory Insights for the ANA+ Consult A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD) https://t.co/5RgA143wLb https://t.co/JZU7ZX3Gty

AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It is considered an orphan disease because of its low prevalence - reported anywhere between 16 to 40 per ten million. https://t.co/Hw9RECWYg5 https://t.co/A5JMCSpl0D

Time to Risk Stratify Methotrexate Lab Monitoring? A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy. https://t.co/R2TOzSO6cx https://t.co/XY3XEkSCT6

RA and cancer risk in the biologic era RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era. https://t.co/ZOWFKTg3l3 https://t.co/1VLWgxVb0W

FDA Approves Colchicine for CV Prevention. The FDA has approved colchicine for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such an indication. https://t.co/g6j9yvl1n2 https://t.co/RUip1o4MYZ

Best of 2023: 2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic CPPD disease is unknown. https://t.co/gsCtfHzn4Z https://t.co/lIaf36epZY

Best of 2023: How Being a Patient Taught Me to Be a Better Doctor Since I can remember, I always wanted to be a doctor. My dad was a trauma surgeon and my mom a nurse. https://t.co/JE4QoJy4jp https://t.co/jrJoqRD30P

Best of 2023: LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/5nzq6KvOpy https://t.co/Y2MCXkGck2

STOP-RA study on HCQ preventing RA... HCQ did NOT prevent RA development in pre-RA pts #RNL2023 https://t.co/BqZlajMOLK https://t.co/Omui3LWiPi

Avacopan in GPA - non-inferior to prednisone for induction remission - received FDA approval for treatment of severe active GPA in combo with standard therapy and steroids - should be used in newly diagnosed active or relapsing disease @rheumnow #RNL2023 https://t.co/yxujTvbVGp https://t.co/UfOkrJDgcU

Full Read comprehensive review by Isenberg et al-what Rx works in SLE; review of RCT data on approved & developing drugs: - Obinutuzumab - Dapirolizumab - Deucravacitinib - Litifilimab - Atacicept - Telitacicept https://t.co/4JvbZ6ysWn https://t.co/FePnuTsHhN